Novo Nordisk A/s Share Price (NYSE: NVO)

$54.28

▲

1.87

(3.57%)

Live

Last updated on August 19, 2025 at 12:39 AM IST

$₹

Check the interactive Novo Nordisk A/s Stock chart to analyse performance

Novo Nordisk A/s stock performance

as on August 19, 2025 at 12:39 AM IST

Today's Low:$54.06
Today's High:$54.89
$54.28
0.41%
Downside
Day's Volatility :1.51%
Upside
1.11%
52 Weeks Low:$45.05
52 Weeks High:$139.74
$54.28
17.0%
Downside
52 Weeks Volatility :67.76%
Upside
61.16%

Novo Nordisk A/s Stock Returns

Period	Novo Nordisk A/s	Sector (Health Care)	Index (Russel 2000)
3 Months	-21.8%	2.3%	0.0%
6 Months	-36.34%	-5.8%	0.0%
1 Year	-61.25%	-10.9%	0.0%
3 Years	0.26%	2.8%	-11.6%

Novo Nordisk A/s Key Stats

Check Novo Nordisk A/s key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$52.41
Open	$51.43
Today's High	$54.89
Today's Low	$53.93
Market Capitalization	$226.3B
Today's Volume	$16.0M
52 Week High	$139.735
52 Week Low	$45.05
Revenue TTM	$311.9B
EBITDA	$159.3B
Earnings Per Share (EPS)	$3.92
PE Ratio	13.37
Dividend Yield	3.08%
Profit Margin	35.61%
Quarterly Earnings Growth YOY	0.33%
Return On Equity TTM	79.17%

Stock Returns calculator for Novo Nordisk A/s Stock including INR - Dollar returns

The Novo Nordisk A/s stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Novo Nordisk A/s investment value today

Current value as on today

₹44,207

Returns

₹55,793

(-55.79%)

Returns from Novo Nordisk A/s Stock

₹59,867 (-59.87%)

Dollar Returns*

₹4,073 (+4.07%)

Indian investors sentiment towards Novo Nordisk A/s Stock

221.13%

Period: Jul 18, 2025 to Aug 17, 2025. Change in 30 Days versus previous period

Investment in Novo Nordisk A/s Shares from India has grown by 221.13% over the past 30 days, indicating increased transactional activity.

369%

Period: Jul 18, 2025 to Aug 17, 2025. Change in 30 Days versus previous period

Search interest for Novo Nordisk A/s Stock from India on INDmoney has increased by 369% in the last 30 days, reflecting an upward trend in search activity.

Indian Mutual Funds that invest in Novo Nordisk A/s Stock

Name	Shares Held	Change in Shares	% of Assets
DSP Value Fund Direct Plan Growth	18898	-	0.74%
DSP Multi Asset Allocation Fund Direct Growth	58967	-	0.67%
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth	5007	0.00	1.25%
Axis Innovation Fund Direct Growth	5887	-139.64	0.20%

Global Institutional Holdings in Novo Nordisk A/s

Name
Holdings %
Name
Holdings %
Jennison Associates LLC
0.43%
Bank of America Corp
0.33%
Loomis, Sayles & Company LP
0.28%
Morgan Stanley - Brokerage Accounts
0.28%
Capital Research & Mgmt Co - Division 3
0.26%
Fayez Sarofim & Company
0.25%

Analyst Recommendation on Novo Nordisk A/s Stock

Rating

Trend

Buy

62%Buy

31%Hold

6%Sell

Based on 32 Wall street analysts offering stock ratings for Novo Nordisk A/s(by analysts ranked 0 to 5 stars)

Novo Nordisk A/s Share Price Target

What analysts predicted

Upside of 24.27%

Target:

$67.45

Current:

$54.28

Novo Nordisk A/s share price target is $67.45, a slight Upside of 24.27% compared to current price of $54.28 as per analysts' prediction.

Novo Nordisk A/s Stock Insights

Price Movement
In the last 1 year, NVO stock has moved down by -61.1%
Decreasing Revenue
Novo Nordisk A/S has experienced a decline in revenue over the last three quarters. The revenue has decreased from $85.68 billion to $76.85 billion, representing an average decline of 5.2% per quarter.
Decreasing Net Profit
Novo Nordisk A/S has experienced a decline in net profit over the last two quarters. Specifically, their net profit decreased from $29.03 billion to $26.50 billion, which represents an average decrease of about 8.7% per quarter.
NVO vs JNJ (1 yr)
In the last 1 year, Johnson & Johnson has given 10.8% return, outperforming this stock by 71.9%
NVO vs LLY (3 yr)
In the last 3 years, Eli Lilly And Company has given 5.9% return, outperforming this stock by 3.9%
Price to Sales
Novo Nordisk A/S has a price-to-sales ratio of 0.7, meaning that investors are willing to pay $0.70 for every $1 of sales the company generates. In comparison, Johnson & Johnson has a much higher price-to-sales ratio of 4.7, indicating that investors are willing to pay $4.70 for every $1 of sales from that company.

Novo Nordisk A/s Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$18.1B	↑ 9.11%
Net Income	$5.8B	↑ 0.84%
Net Profit Margin	31.92%	↓ 2.62%

	FY20	Y/Y Change
Revenue	$20.7B	↑ 4.04%
Net Income	$6.9B	↑ 8.18%
Net Profit Margin	33.19%	↑ 1.27%

	FY21	Y/Y Change
Revenue	$21.4B	↑ 10.91%
Net Income	$7.3B	↑ 13.33%
Net Profit Margin	33.92%	↑ 0.73%

	FY22	Y/Y Change
Revenue	$25.2B	↑ 25.68%
Net Income	$7.9B	↑ 16.27%
Net Profit Margin	31.38%	↓ 2.54%

	FY23	Y/Y Change
Revenue	$34.0B	↑ 31.26%
Net Income	$12.3B	↑ 50.71%
Net Profit Margin	36.03%	↑ 4.65%

	FY24	Y/Y Change
Revenue	$40.7B	↑ 25.03%
Net Income	$14.2B	↑ 20.68%
Net Profit Margin	34.78%	↓ 1.25%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$9.5B	↓ 0.78%
Net Income	$3.7B	↑ 15.68%
Net Profit Margin	38.88%	↑ 5.53%

	Q2 FY24	Q/Q Change
Revenue	$9.8B	↑ 4.15%
Net Income	$2.9B	↓ 21.08%
Net Profit Margin	29.46%	↓ 9.42%

	Q3 FY24	Q/Q Change
Revenue	$10.6B	↑ 4.78%
Net Income	$4.1B	↑ 36.16%
Net Profit Margin	38.28%	↑ 8.82%

	Q4 FY24	Q/Q Change
Revenue	$12.0B	↑ 20.15%
Net Income	$4.0B	↑ 3.4%
Net Profit Margin	32.95%	↓ 5.33%

	Q1 FY25	Q/Q Change
Revenue	$11.3B	↓ 8.87%
Net Income	$4.2B	↑ 2.85%
Net Profit Margin	37.18%	↑ 4.23%

	Q2 FY25	Q/Q Change
Revenue	$76.9B	↓ 1.58%
Net Income	$26.5B	↓ 8.72%
Net Profit Margin	34.48%	↓ 2.7%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$15.2B	↑ 8.19%

	FY20	Y/Y Change
Profit	$17.3B	↑ 4.0%

	FY21	Y/Y Change
Profit	$17.8B	↑ 10.5%

	FY22	Y/Y Change
Profit	$21.1B	↑ 26.77%

	FY23	Y/Y Change
Profit	$28.8B	↑ 32.32%

	FY24	Y/Y Change
Profit	$34.5B	↑ 25.13%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$8.1B	↓ 0.74%

	Q2 FY24	Q/Q Change
Profit	$8.3B	↑ 4.24%

	Q3 FY24	Q/Q Change
Profit	$8.9B	↑ 3.84%

	Q4 FY24	Q/Q Change
Profit	$10.2B	↑ 21.09%

	Q1 FY25	Q/Q Change
Profit	$9.5B	↓ 10.27%

	Q2 FY25	Q/Q Change
Profit	$64.0B	↓ 1.82%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$7.0B	↑ 4.85%
Investing Cash Flow	$-1.7B	↓ 4.73%
Financing Cash Flow	$-5.3B	↑ 2.79%

	FY20	Y/Y Change
Operating Cash Flow	$8.5B	↑ 11.05%
Investing Cash Flow	$-3.7B	↑ 94.94%
Financing Cash Flow	$-5.3B	↓ 9.13%

	FY21	Y/Y Change
Operating Cash Flow	$8.4B	↑ 5.87%
Investing Cash Flow	$-4.8B	↑ 40.87%
Financing Cash Flow	$-3.9B	↓ 20.94%

	FY22	Y/Y Change
Operating Cash Flow	$11.2B	↑ 43.43%
Investing Cash Flow	$-3.5B	↓ 21.16%
Financing Cash Flow	$-7.4B	↑ 103.18%

	FY23	Y/Y Change
Operating Cash Flow	$15.9B	↑ 38.06%
Investing Cash Flow	$-6.4B	↑ 76.15%
Financing Cash Flow	$-9.2B	↑ 21.93%

	FY24	Y/Y Change
Operating Cash Flow	$17.0B	↑ 11.07%
Investing Cash Flow	$-18.1B	↑ 193.66%
Financing Cash Flow	$1.2B	↓ 113.83%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$2.1B	↑ 49.87%
Investing Cash Flow	$576.6M	↓ 126.88%
Financing Cash Flow	$-3.8B	↑ 160.79%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$7.3B	↑ 252.82%
Investing Cash Flow	$-3.0B	↓ 624.04%
Financing Cash Flow	$2.4B	↓ 163.24%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$6.5B	↓ 13.17%
Investing Cash Flow	$-3.1B	↑ 0.83%
Financing Cash Flow	$-2.7B	↓ 210.3%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$1.7B	↓ 71.95%
Investing Cash Flow	$-12.8B	↑ 336.36%
Financing Cash Flow	$5.2B	↓ 300.18%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$3.6B	↑ 99.91%
Investing Cash Flow	$-967.4M	↓ 92.68%
Financing Cash Flow	$790.2M	↓ 85.2%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$40.8B	↑ 65.85%
Investing Cash Flow	$-14.2B	↑ 113.52%
Financing Cash Flow	$-46.2B	↓ 948.1%

Novo Nordisk A/s Technicals Summary

Sell

Neutral

Buy

Novo Nordisk A/s is currently in a neutral trading position according to technical analysis indicators.

Novo Nordisk A/s Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Novo Nordisk A/s	-19.27%	-36.34%	-61.25%	0.26%	57.32%
Eli Lilly And Company	-8.0%	-18.2%	-23.93%	117.25%	360.46%
Johnson & Johnson	7.47%	13.97%	10.66%	4.33%	17.45%
Merck & Co. Inc.	6.18%	1.1%	-26.4%	-8.55%	-0.96%
Abbvie Inc	11.81%	5.32%	4.99%	45.71%	115.08%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Novo Nordisk A/s	13.37	13.37	1.54	24.84	0.79	0.22	0.03	37.82
Eli Lilly And Company	45.86	45.86	1.01	22.82	0.86	0.17	0.01	20.38
Johnson & Johnson	18.69	18.69	1.06	10.85	0.3	0.08	0.03	32.6
Merck & Co. Inc.	12.98	12.98	0.83	8.93	0.35	0.13	0.04	19.57
Abbvie Inc	97.96	97.96	0.44	11.97	1.13	0.09	0.03	-0.1

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Novo Nordisk A/s	Buy	$226.3B	57.32%	13.37	35.61%
Eli Lilly And Company	Buy	$628.6B	360.46%	45.86	25.91%
Johnson & Johnson	Buy	$420.1B	17.45%	18.69	25.0%
Merck & Co. Inc.	Buy	$210.3B	-0.96%	12.98	25.79%
Abbvie Inc	Buy	$365.1B	115.08%	97.96	6.45%

Novo Nordisk A/s Dividend announcements

Novo Nordisk A/s Dividends September, 2025
In the quarter ending September,2025. Novo Nordisk A/s has declared dividend of $0.58

About Novo Nordisk A/s

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Organization	Novo Nordisk A/s
Employees	78387
CEO	Mr. Maziar Mike Doustdar
Industry	Health Technology

Key Management of Novo Nordisk A/s

Name	Title
Mr. Karsten Munk Knudsen	Executive VP, CFO & Member of the Management Board
Mr. Maziar Mike Doustdar	President, CEO, EVP of International Operations & Member of the Management Board
Mr. Henrik Ehlers Wulff	Executive VP of CMC & Product Supply and Member of the Management Board
Mr. Ludovic Helfgott	Executive VP of Product & Portfolio Strategy and Member of Management Board
Dr. Martin Holst Lange	EVP of Development, CSO & Member of the Management Board
Ms. Tania Sabroe	EVP of People, Organisation and Corporate Affairs & Member of Management Board
Mr. David S. Moore	Executive VP of US Operations & Member of Management Board
Ms. Thilde Hummel Bogebjerg	Executive VP of Quality, IT & Environmental Affairs and Member of Management Board
Jacob Martin Wiborg Rode	Head of Investor Relations
Mr. John F. Kuckelman	Group General Counsel

Important FAQs about investing in NVO Stock from India :

What is Novo Nordisk A/s share price today?

Novo Nordisk A/s share price today is $54.28 as on August 19, 2025 at 12:39 AM IST. Novo Nordisk A/s share today touched a day high of $54.89 and a low of $54.06.

What is the 52 week high and 52 week low for Novo Nordisk A/s share?

Novo Nordisk A/s share touched a 52 week high of $139.74 and a 52 week low of $45.05. Novo Nordisk A/s stock price today, August 19, 2025 at 12:39 AM IST is trending at $54.28, lower by 61.16% versus the 52 week high.

How to invest in Novo Nordisk A/s Stock (NVO) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Novo Nordisk A/s on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Novo Nordisk A/s Shares that will get you 0.0276 shares as per Novo Nordisk A/s share price of $54.28 per share as on August 19, 2025 at 12:39 AM IST.

What is the minimum amount required to buy Novo Nordisk A/s Stock (NVO) from India?

Indian investors can start investing in Novo Nordisk A/s (NVO) shares with as little as ₹87.3775 or $1 (as of August 18, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹873.77 in Novo Nordisk A/s stock (as per the Rupee-Dollar exchange rate as on August 18, 2025). Based on Novo Nordisk A/s share’s latest price of $54.28 as on August 19, 2025 at 12:39 AM IST, you will get 0.1842 shares of Novo Nordisk A/s. Learn more about fractional shares .

What are the returns that Novo Nordisk A/s has given to Indian investors in the last 5 years?

Novo Nordisk A/s stock has given 57.32% share price returns and 16.91% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?